An interview with Richard Brudnick, Senior VP, Corporate Development, Biogen De-risking has evolved from literature searches to the cultivation of many wide-ranging relationships throughout the life sciences strata, according to Richard Brudnick, Senior VP, Corporate Development at Biogen. In a recent interview, Brudnick outlined key strategies to accessing innovation and “de-risking” risk through collaboration.

Sorrento Therapeutics agreed to sell its drug candidate Cynviloq (paclitaxel nanoparticle polymeric micelle) for up to $1.3 billion to NantPharma.

Agilis Biotherapeutics has entered into an exclusive worldwide license agreement with the University of South Florida for the treatment of using gene therapy technology developed by Edwin Weeber, PhD, Director of the Neurobiology of Learning and Memory and Chief Scientific Officer at the USF Health Byrd Alzheimer’s Research Institute at the University of South Florida, more »

Pfizer has acquired a minority equity interest in AM-Pharma and secured an exclusive option to acquire the remaining equity in the company.

EMD Serono has begun co-promoting Pfizer’s anaplastic lymphoma kinase (ALK) inhibitor XALKORI (crizotinib) as part of its global strategic alliance with Pfizer.

23andMe announced the launch of the Lupus Research Study in collaboration with Pfizer.

Bayer HealthCare has entered into an exclusive license agreement with Isis Pharmaceuticals on ISIS-FXIRx

4D Molecular Therapeutics announced a collaboration and license agreement with Roche to discover and develop optimized next-generation AAV vectors

Innate Pharma has signed a co-development and commercialization agreement with AstraZeneca

Celgene has entered into a strategic collaboration with MedImmune to develop and commercialize an anti-PD-L1 inhibitor, MEDI4736, for hematologic malignancies